论文部分内容阅读
截至发稿前,记者从深圳赛百诺公司获悉,该公司独立研发的广谱抗癌药重组人p53腺病毒注射液(商品名:“今又生”Gendicine)将于2月10日正式上市。去年10月“今又生”经国家食品药品监督管理局批准,获得国家一类新药证书。据悉,该药是国家药监局批准的第一个进入临床试验的基因治疗药品,也是世界上第一个获得新药证书和获准
As of press time ago, the reporter learned from Shenzhen SaiBenOn company, the company independently developed a broad-spectrum anti-cancer drug recombinant adenovirus p53 (trade name: “now again” Gendicine) will be officially listed on February 10. Last October, “Now and then” by the State Food and Drug Administration approval, access to a national class of new drug certificate. It is reported that the drug is the first approved by the State Food and Drug Administration to enter clinical trials of gene therapy drugs, but also the world’s first new drug certificate and permission